H.C. Wainwright raised the firm’s price target on Nuvation Bio (NUVB) to $18 from $10 and keeps a Buy rating on the shares. The firm cites its revised Ibtrozi revenue forecasts for the target increase.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio’s IBTROZI Gains Buy Rating Amid Increased Market Penetration and Extended Therapy Duration
- Largest borrow rate increases among liquid names
- Nuvation Bio management to meet with B. Riley
- Nuvation Bio publishes safusidenib study results
- Strategic Pipeline Adjustments and Promising Developments Justify Buy Rating for Nuvation Bio